scholarly journals Peripheral Eosinophil Counts Correlate With Nasal Eosinophil Counts in Patients With Rhinitis

2018 ◽  
Vol 28 (6) ◽  
pp. 428-430 ◽  
Author(s):  
G Ciprandi ◽  
A Varricchio ◽  
G Tajana ◽  
I La Mantia ◽  
C Tommasino
Keyword(s):  
Peripheral Eosinophil ◽  
Eosinophil Counts

Eosinophilia as a marker of resistance to Teladorsagia circumcincta in Scottish Blackface lambs

Parasitology ◽  
2002 ◽  
Vol 124 (5) ◽  
pp. 553-560 ◽  
Author(s):  
M. J. STEAR ◽  
N. G. HENDERSON ◽  
A. KERR ◽  
Q. A. MCKELLAR ◽  
S. MITCHELL ◽  
...  
Keyword(s):  
Peripheral Blood ◽  
Gastrointestinal Nematodes ◽  
Blood Eosinophil ◽  
Peripheral Blood Eosinophil ◽  
Teladorsagia Circumcincta ◽  
Peripheral Eosinophil ◽  
Faecal Egg Counts ◽  
Eosinophil Counts

Faecal egg counts and peripheral blood eosinophil counts were taken from Scottish Blackface lambs following natural, predominantly Teladorsagia circumcincta infection. Peripheral eosinophil concentrations were higher in animals with lower egg counts but only in lambs that were at least 3 months of age. The reduced egg counts were due to reduced fecundity of T. circumcincta; there was no association with the number of adult T. circumcincta. Associations with the number of parasites from other species of gastrointestinal nematodes appeared to be neutral or favourable. Estimated heritabilities for eosinophil concentrations in 4- and 5-month-old lambs were 0·48±0·16 and 0·43±0·17, respectively. Therefore, under defined circumstances, eosinophil concentrations may be a useful indicator of resistance to predominantly T. circumcincta infection.

scholarly journals The Impact of Peripheral Eosinophil Counts and Eosinophil to Lymphocyte Ratio (ELR) in the Clinical Course of COVID-19 Patients: A Retrospective Study

In Vivo ◽  
2021 ◽  
Vol 35 (1) ◽  
pp. 641-648
Author(s):  
VASILIKI E. GEORGAKOPOULOU ◽  
NIKOLAOS GARMPIS ◽  
CHRISTOS DAMASKOS ◽  
SERENA VALSAMI ◽  
DIMITRIOS DIMITROULIS ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Clinical Course ◽  
Lymphocyte Ratio ◽  
Peripheral Eosinophil ◽  
The Impact ◽  
Eosinophil Counts

Long-term Follow-up of Symptoms and Peripheral Eosinophil Counts in Seven Children with Eosinophilic Esophagitis

2004 ◽  
Vol 38 (4) ◽  
pp. 452-456 ◽  
Author(s):  
Stefania Esposito ◽  
Daniela Marinello ◽  
Roberta Paracchini ◽  
Paola Guidali ◽  
Giuseppina Oderda
Keyword(s):  
Eosinophilic Esophagitis ◽  
Long Term Follow Up ◽  
Peripheral Eosinophil ◽  
Eosinophil Counts

scholarly journals Effects of Leukotriene Receptor Antagonists on Peripheral Eosinophil Counts and Serum IgE Levels in Children with Food Allergy

Drugs in R&D ◽  
2010 ◽  
Vol 10 (3) ◽  
pp. 147-154 ◽  
Author(s):  
Yoko Yamakawa ◽  
Yoshikazu Ohtsuka ◽  
Kiyotaka Ohtani ◽  
Tohru Fujii ◽  
Satoru Nagata ◽  
...  
Keyword(s):  
Food Allergy ◽  
Receptor Antagonists ◽  
Serum Ige ◽  
Leukotriene Receptor Antagonists ◽  
Leukotriene Receptor ◽  
Peripheral Eosinophil ◽  
Eosinophil Counts

Falls in Peripheral Eosinophil Counts Parallel the Late Asthmatic Response

1989 ◽  
Vol 139 (2) ◽  
pp. 458-462 ◽  
Author(s):  
W. O. C. M. Cookson ◽  
C. F. Craddock ◽  
M. K. Benson ◽  
S. R. Durham
Keyword(s):  
Asthmatic Response ◽  
Late Asthmatic Response ◽  
Peripheral Eosinophil ◽  
Eosinophil Counts

scholarly journals Association Between Asthma Control Test, Peripheral Eosinophil Counts, and Serum Total Immunoglobulin E Levels in Severe Asthmatics

2016 ◽  
Vol 137 (2) ◽  
pp. AB206
Author(s):  
Santiago Alvarez Arango ◽  
Jennifer Toh ◽  
Denisa Ferastraoaru ◽  
Gabriele de Vos ◽  
David L. Rosenstreich ◽  
...  
Keyword(s):  
Asthma Control ◽  
Immunoglobulin E ◽  
Control Test ◽  
Asthma Control Test ◽  
Peripheral Eosinophil ◽  
Eosinophil Counts ◽  
Total Immunoglobulin

scholarly journals Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Arian Ghassemian ◽  
Jane Jiyoon Park ◽  
Michael W. Tsoulis ◽  
Harold Kim
Keyword(s):  
Eosinophil Count ◽  
Retrospective Chart Review ◽  
Eosinophilic Asthma ◽  
Interleukin 5 ◽  
Severe Eosinophilic Asthma ◽  
The Mean ◽  
Baseline Characteristics ◽  
Peripheral Eosinophil ◽  
Pre Treatment ◽  
Eosinophil Counts

Abstract Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on eosinophils. Both therapies reduce oral corticosteroid requirements and asthma exacerbations. However, no head-to-head studies have been published. The aim of the present study was to compare the efficacy of peripheral eosinophil reduction of mepolizumab and benralizumab. Methods A retrospective chart review was conducted on patients with severe eosinophilic asthma who were approved for either IL-5 agent. Patients with noted non-adherence or those who were on fluctuating doses of corticosteroids for non-asthma related illnesses were excluded. The last detectable eosinophil count for each patient prior to start of therapy was compared to the highest eosinophil count noted after therapy start with at least 30 days of adherence. Results Thirty-six patients taking mepolizumab and 19 patients taking benralizumab met the inclusion criteria and had both pre-treatment and post-treatment eosinophil counts. Baseline characteristics were not statistically different between those on mepolizumab and benralizumab therapy. The mean pre-therapy serum eosinophil count did not statistically differ between patients on mepolizumab (597.2 cells/µL) compared to benralizumab (521.6 cells/µL), p = 0.3769. While both therapies resulted in a significant decrease in eosinophil count (p < 0.0001); the mean decrease did not statistically differ between patients taking mepolizumab compared to those on benralizumab, p = 0.9079. Nonetheless, 100% of patients receiving benralizumab had undetectable eosinophil counts post-therapy compared to 31% of patients receiving mepolizumab (p < 0.0001). Conclusion Both mepolizumab and benralizumab are potent targets of the IL-5 pathway with the ability to significantly reduce peripheral eosinophil counts. While there is there is no statistical difference in the magnitude of eosinophil reduction offered by each agent, benralizumab is able to decrease peripheral eosinophil counts to 0 cells/µL in more patients than mepolizumab.

Sign in / Sign up

Export Citation Format

Share Document